HomeAboutAbout Team

Dr. Shrikrishna Dadke has gained 24 years of valuable experience in drug discovery and mechanism of action studies while working in USA and India. Dr. Dadke earned his PhD in 1997 from Cancer Research Institute (now known as ACTREC), Univ. of Mumbai, India. Dr. Dadke then worked at Abbott Laboratories, Chicago, USA in the Metabolic Disorders Program. He was involved in the identification and validation of novel targets in the area of Type II Diabetes. Post his tenure at Abbott Laboratories, Dr. Dadke worked at Fox Chase Cancer Center in Philadelphia, USA, where he continued his research in the field of Diabetes. His research resulted in a Nature Cell Biology publication which was cited as a “hot article” by the journal. Upon his return from the USA, Dr. Dadke worked at Dr. Reddy’s Laboratories, Lupin Ltd., and Vimta Labs Ltd. His work has contributed to IND filings and he has also been involved in due diligence activities.

Senior Vice President & Scientific Director, Fox Chase Cancer Center, Philadelphia, PA, USA.

Dr. Chernoff is Senior Vice President, Scientific Director and Stanley P. Reimann Chair in Oncology Program at Fox Chase Cancer Center in Philadelphia. He received his MD and PhD from Mount Sinai School of Medicine. Dr. Chernoff has devoted his research career to understanding how cells receive and interpret signals, and how this process in corrupted in cancer. In particular, he has focused on the regulation of signal transduction by phosphorylation, with the overarching goal to understand the mechanisms underlying how signal transduction pathways are rewired in cancer, and their implications for the development, spread, and resistance of solid tumors to therapy.

Professor of Medicine, Director, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.

Dr. Neel is the Director of the Laura and Isaac Perlmutter Cancer Center and Professor of Medicine at NYU Langone Health in New York City. His research focuses on cellular signaling, with a particular interest in the biology and regulation of protein-tyrosine kinases and protein-tyrosine phosphatases, the role of RAS/ERK pathway mutations in developmental disease and malignancy, and the biology of ovarian cancer. Dr. Neel earned his PhD in viral oncology from The Rockefeller University in 1982 and his MD from Cornell University Medical School the following year. His graduate work on oncogene activation by slowly transforming RNA tumor viruses had major impact on the field. He previously held positions as William B. Castle Chair of Medicine at Harvard Medical School and Director of Hematology-Oncology Research and Head of the Cancer Biology Program at Beth Israel Deaconess Medical Center, Boston and as Director of Research at Princess Margaret Cancer Center and Professor of the Medical Biophysics at the University of Toronto, Ontario, Canada. He has authored >240 primary papers and 33 reviews, many in leading journals including Cell, Molecular Cell, Developmental Cell, Science, Nature, Nature Medicine and Nature Genetics. His work has been cited >46,000 times (h-index, 110). He is an elected member of the American Association of Physicians, former Program Chair of the Annual Meeting and Member of Board of Directors of AACR, recipient of the Gertrude Elion Award of AACR and the Premier of Ontario Summit Award, and co-founder of Northern Biologics, a company focusing on antibody therapeutics for cancer and Navire Pharmaceuticals, which is developing SHP2 inhibitors for cancer.